Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athersys, Inc. stock logo
ATHX
Athersys
$0.00
$0.01
▼
$1.99
$833K-0.91.77 million shsN/A
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.26
-8.2%		$0.30
$0.15
▼
$0.97
$849K-0.25,619 shs2,757 shs
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$0.12
-6.1%		$0.16
$0.10
▼
$2.83
$810K2.074.35 million shs558,930 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
▼
$0.10
$386K0.13282,029 shs104,100 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athersys, Inc. stock logo
ATHX
Athersys
0.00%0.00%0.00%0.00%0.00%
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
+3.96%-6.59%+7.96%-6.43%-51.06%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
0.00%+5.35%-8.13%-43.97%-94.94%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
+40.00%+40.00%+16.67%+16.67%-65.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athersys, Inc. stock logo
ATHX
Athersys
$0.00
$0.01
▼
$1.99
$833K-0.91.77 million shsN/A
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.26
-8.2%		$0.30
$0.15
▼
$0.97
$849K-0.25,619 shs2,757 shs
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$0.12
-6.1%		$0.16
$0.10
▼
$2.83
$810K2.074.35 million shs558,930 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
▼
$0.10
$386K0.13282,029 shs104,100 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athersys, Inc. stock logo
ATHX
Athersys
0.00%0.00%0.00%0.00%0.00%
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
+3.96%-6.59%+7.96%-6.43%-51.06%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
0.00%+5.35%-8.13%-43.97%-94.94%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
+40.00%+40.00%+16.67%+16.67%-65.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Athersys, Inc. stock logo
ATHX
Athersys
0.00
N/AN/AN/A
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
0.00
N/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
1.00
SellN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SRNE, ATXI, ATHX, and IMCC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Athersys, Inc. stock logo
ATHX
Athersys
$146K0.00N/AN/A($1.33) per share0.00
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$1.92 per shareN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$39.17M0.02N/AN/A($0.49) per share-0.25
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M0.01N/AN/AN/A∞
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Athersys, Inc. stock logo
ATHX
Athersys
-$72.53M-$2.03N/AN/AN/AN/AN/A-223.03%N/A
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M-$0.850.01N/AN/AN/A-471.57%-296.50%N/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-$8.10M-$1.75N/AN/AN/A-39.62%-585.96%-54.55%N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84M-$0.17N/AN/AN/AN/AN/AN/A8/18/2026 (Estimated)

Latest SRNE, ATXI, ATHX, and IMCC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/18/2026N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.42N/AN/AN/A$18.23 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Athersys, Inc. stock logo
ATHX
Athersys
N/AN/AN/AN/AN/A
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Athersys, Inc. stock logo
ATHX
Athersys
N/A
0.06
0.06
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
2.70
2.70
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A
0.55
0.47
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Athersys, Inc. stock logo
ATHX
Athersys
19.35%
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
17.34%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
7.68%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%

Insider Ownership

CompanyInsider Ownership
Athersys, Inc. stock logo
ATHX
Athersys
0.03%
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
8.60%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
5.91%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Athersys, Inc. stock logo
ATHX
Athersys
2461.72 million61.70 millionNo Data
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
43.30 million2.02 millionNot Optionable
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
3406.22 million5.86 millionNot Optionable
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
800551.28 million536.95 millionNo Data

Recent News About These Companies

Sorrento Voyage Announces Expanded Luxury Boat Tours and Proposal Experiences Along the Amalfi Coast
January 5, 2026  |  newsfilecorp.comN
Sorrento Therapeutics Inc (SRNE) - Investing.com
July 3, 2025  |  investing.comhttps://www.investing.com/equities/sorrento-therape-opinion
SRNE Sorrento Therapeutics, Inc. - Seeking Alpha
June 29, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/SRNE
Sorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | Benzinga
April 19, 2025  |  benzinga.comhttps://www.benzinga.com/quote/SRNE
Sorrento Shareholders Lose Discovery Bid Over Judge Relationship
March 28, 2025  |  news.bloomberglaw.comN
Scilex says bankruptcy court extends lockup period on shares of Scilex dividend
January 31, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scilex-says-bankruptcy-court-extends-lockup-period-on-shares-of-scilex-dividend-1034296170
DSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel Infills
October 24, 2024  |  newsfilecorp.comN
Sorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO says
August 20, 2024  |  msn.comhttps://www.msn.com/en-us/health/medical/sorrento-enrols-60-of-80-patient-phase-ii-target-for-abivertinib-in-covid-19-futility-analysis-potentially-in-a-month-ceo-says/ar-AA1p7arP
Sorrento Resources to Sell Three Newfoundland Properties to Gold Hunter
May 29, 2024  |  newsfilecorp.comN
Sorrento Therapeutics Inc (SRNE)
May 25, 2024  |  investing.comhttps://www.investing.com/equities/sorrento-therape-opinion/3
Sorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified Person
May 8, 2024  |  newsfilecorp.comN
DSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh Railing
May 1, 2024  |  newsfilecorp.comN
Sorrento Therapeutics Inc SRNE
April 26, 2024  |  morningstar.comM
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
March 27, 2024  |  news.bloomberglaw.comN
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
March 27, 2024  |  news.bloomberglaw.comN
Sorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)
March 12, 2024  |  news.bloomberglaw.comN
Judge Declines to Dismiss Sorrento Therapeutics Bankruptcy Case
March 12, 2024  |  wsj.comhttps://www.wsj.com/articles/judge-declines-to-dismiss-sorrento-therapeutics-bankruptcy-case-8321bd69
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
February 27, 2024  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2024/02/27/9968471.htm
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
February 27, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20240227926537/en/virpax-pharmaceuticals-announces-proposed-settlement-of-litigation-with-sorrento-therapeutics-inc.-and-scilex-pharmaceuticals-inc./
Sorrento Therapeutics
February 7, 2024  |  pharmaphorum.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Athersys stock logo

Athersys NASDAQ:ATHX

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

Avenue Therapeutics stock logo

Avenue Therapeutics NASDAQ:ATXI

$0.26 -0.02 (-8.23%)
As of 02:04 PM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

IM Cannabis stock logo

IM Cannabis NASDAQ:IMCC

$0.12 -0.01 (-6.08%)
Closing price 04:00 PM Eastern
Extended Trading
$0.12 0.00 (-3.36%)
As of 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

Sorrento Therapeutics stock logo

Sorrento Therapeutics NASDAQ:SRNE

$0.0007 0.00 (0.00%)
As of 01:27 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas